Positive results in Phase III trial of Xeljanz (Pfizer) in patients with Rheumatoid Arthritis
A Phase III clinical trial demonstrates that Xeljanz (tofacitinib), from Pfizer, improves disease activity and inhibits progression of joint damage in Rheumatoid Arthritis (RA) patients who did not respond to methotrexate (MTX). In this 24-month, double-blind, placebo-controlled study, 797 participants were randomized to receive 5mg of tofacitinib (n=321); 10 mg of tofacitinib (n=316) or placebo. Results from a 12-month interim analysis show that tofacitinib is effective in preserving joint structure in patients who had an inadequate response to MTX therapy.
The difference from placebo in mean change from baseline in the van der Heijde modified total Sharp score was statistically significant for tofacitinib at 10mg BID but not at 5mg BID at month six (co-primary endpoint) and month 12. Xeljanz was approved by the FDA for treating RA in November 2012. Results appear in Arthritis & Rheumatism. See: �Tofacitinib (CP-690,550) in Patients with Rheumatoid Arthritis on Methotrexate: 12-Month Data from a 24-Month Phase 3 Randomized Radiographic Study.� Desiree van der Heijde et al. Arthritis and Rheumatism; January 24, 2013 DOI: 10.1002/art.37816
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.